IP: Use at a dilution of 1/250. WB: Use at a dilution of 1/500. Detects a bands corresponding to at least three PDE11A variants (approximately 57, 65 and 80 kDa). Optimal dilutions/concentrations should be determined by the end user.
Rat testis, skeletal muscle, kidney and brain
This antibody does not cross-react with any of the members of the PDE family tested so far.
'Stabilization buffer' with 0.02% thimerosal or merthiolate.
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
0.7-0.75 mg/ml (Please refer to the vial label for the specific concentration.)
Synthetic peptide (Human) (N terminal).
Immunogen affinity purified
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
One of the many phosphodiesterases that compartmentalize and hydrolyze cAMP and cGMP into AMP and GMP is Phosphodiesterase type 11. The human PDE11A contains an open reading frame encoding a 490 amino acid protein (55-56 kDa). The PDE11A has an N-terminus GAF domain homologous to other signaling molecule as found in PDE2, PDE5, PDE6, PDE10, which potentially represents an allosteric cGMP and other small signaling molecules. PDE11A hydrolyzes both cGMP and cAMP; it is sensitive to non-selective PDE inhibitor IBMX as well as zaprinast and dipyrimadole inhibitors that are generally selective for cGMP-specific enzymes. PDE11A expression is diverse and is found in high levels in skeletal muscle, prostate, kidney, liver, pituitary and testis.
GTX14623 WB Image
Western blot of PC-PD11 with anti PD11 antibodies.
1. GTX14623 1:500 dilution
2. GTX14624 1:500 dilution